{"id":"treatment-viibryd","safety":{"commonSideEffects":[{"rate":"28","effect":"Nausea"},{"rate":"23","effect":"Diarrhea"},{"rate":"12","effect":"Dizziness"},{"rate":"10","effect":"Insomnia"},{"rate":"9","effect":"Somnolence"},{"rate":"7","effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL7257","moleculeType":"Small molecule","molecularWeight":"218.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Viibryd (vilazodone) blocks the reuptake of serotonin at the serotonin transporter and also has partial agonist activity at the 5-HT1A receptor. This dual mechanism increases synaptic serotonin availability while the 5-HT1A agonism may enhance antidepressant efficacy and potentially reduce sexual dysfunction compared to traditional SSRIs.","oneSentence":"Viibryd is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases serotonin and norepinephrine levels in the brain to treat depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:13.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT05422612","phase":"PHASE2","title":"Department of Defense PTSD Adaptive Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2023-11-02","conditions":"Post Traumatic Stress Disorder","enrollment":800},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT01742832","phase":"PHASE2","title":"Double-Blind Treatment of Major Depressive Disorder With Vilazodone","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-05","conditions":"Major Depressive Disorder","enrollment":79},{"nctId":"NCT01878292","phase":"PHASE3","title":"Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-07-11","conditions":"Major Depressive Disorder","enrollment":529},{"nctId":"NCT01629966","phase":"PHASE3","title":"Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-06-30","conditions":"Generalized Anxiety Disorder","enrollment":680},{"nctId":"NCT01766401","phase":"PHASE3","title":"Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-01-31","conditions":"Generalized Anxiety Disorder","enrollment":402},{"nctId":"NCT01844115","phase":"PHASE3","title":"Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-30","conditions":"Generalized Anxiety Disorder","enrollment":415},{"nctId":"NCT02372799","phase":"PHASE3","title":"Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-02-28","conditions":"Major Depressive Disorder","enrollment":473},{"nctId":"NCT02436239","phase":"PHASE3","title":"A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2015-05-02","conditions":"Major Depressive Disorder","enrollment":330},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT01828515","phase":"PHASE2","title":"Vilazodone for Corticosteroid-Induced Memory Impairment","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-12","conditions":"Memory Impairment","enrollment":24},{"nctId":"NCT01608295","phase":"PHASE4","title":"Vilazodone for Treatment of Geriatric Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2012-07","conditions":"Major Depressive Disorder","enrollment":65},{"nctId":"NCT01469377","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12-15","conditions":"Major Depressive Disorder","enrollment":819},{"nctId":"NCT01999920","phase":"PHASE4","title":"Vilazodone for Separation Anxiety Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-12","conditions":"Separation Anxiety Disorder","enrollment":24},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT01715519","phase":"PHASE4","title":"Vilazodone for the Treatment of Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Southern California Institute for Research and Education","startDate":"2012-10","conditions":"PTSD, Depression","enrollment":59},{"nctId":"NCT01574183","phase":"PHASE2","title":"Vilazodone Treatment for Marijuana Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2012-08","conditions":"Marijuana Dependence","enrollment":76},{"nctId":"NCT01573598","phase":"PHASE4","title":"Safety and Efficacy of Vilazodone in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-04","conditions":"Major Depressive Disorder","enrollment":1219},{"nctId":"NCT02097147","phase":"PHASE1","title":"Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2014-03","conditions":"Healthy","enrollment":202},{"nctId":"NCT01712321","phase":"NA","title":"Study of Vilazodone to Treat Social Anxiety Disorder","status":"UNKNOWN","sponsor":"The Medical Research Network","startDate":"2012-10","conditions":"Social Anxiety Disorder","enrollment":30},{"nctId":"NCT00683592","phase":"PHASE3","title":"Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":481},{"nctId":"NCT00285376","phase":"PHASE3","title":"Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response","status":"COMPLETED","sponsor":"Genaissance Pharmaceuticals","startDate":"2006-02","conditions":"Depressive Disorder, Major","enrollment":410}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vilazodone"],"phase":"marketed","status":"active","brandName":"Treatment (Viibryd)","genericName":"Treatment (Viibryd)","companyName":"Southern California Institute for Research and Education","companyId":"southern-california-institute-for-research-and-education","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Viibryd is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases serotonin and norepinephrine levels in the brain to treat depression. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}